Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
Epistemonikos ID: 28e1afc52fc55cd115b7629f99b0bd96a079c738
First added on: Mar 27, 2021